Establishment of CYP2D6 reference samples by multiple validated genotyping platforms

H. Fang, X. Liu, J. Ramírez, N. Choudhury, Michiaki Kubo, H. K. Im, A. Konkashbaev, N. J. Cox, M. J. Ratain, Y. Nakamura, P. H. O'Donnell

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cytochrome P450 2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6)), a highly polymorphic drug-metabolizing enzyme, is involved in the metabolism of one-quarter of the most commonly prescribed medications. Here we have applied multiple genotyping methods and Sanger sequencing to assign precise and reproducible CYP2D6 genotypes, including copy numbers, for 48 HapMap samples. Furthermore, by analyzing a set of 50 human liver microsomes using endoxifen formation from N-desmethyl-tamoxifen as the phenotype of interest, we observed a significant positive correlation between CYP2D6 genotype-assigned activity score and endoxifen formation rate (rs =0.68 by rank correlation test, P=5.3 × 10-8), which corroborated the genotype-phenotype prediction derived from our genotyping methodologies. In the future, these 48 publicly available HapMap samples characterized by multiple substantiated CYP2D6 genotyping platforms could serve as a reference resource for assay development, validation, quality control and proficiency testing for other CYP2D6 genotyping projects and for programs pursuing clinical pharmacogenomic testing implementation.

Original languageEnglish
Pages (from-to)564-572
Number of pages9
JournalPharmacogenomics Journal
Volume14
Issue number6
DOIs
Publication statusPublished - 11-12-2014

Fingerprint

Peptides
HapMap Project
Genotype
Phenotype
Cytochrome P-450 CYP2D6
Liver Microsomes
Tamoxifen
Quality Control
Cytochrome P450 Family 2
Enzymes
Pharmaceutical Preparations
4-hydroxy-N-desmethyltamoxifen

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Fang, H., Liu, X., Ramírez, J., Choudhury, N., Kubo, M., Im, H. K., ... O'Donnell, P. H. (2014). Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics Journal, 14(6), 564-572. https://doi.org/10.1038/tpj.2014.27
Fang, H. ; Liu, X. ; Ramírez, J. ; Choudhury, N. ; Kubo, Michiaki ; Im, H. K. ; Konkashbaev, A. ; Cox, N. J. ; Ratain, M. J. ; Nakamura, Y. ; O'Donnell, P. H. / Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. In: Pharmacogenomics Journal. 2014 ; Vol. 14, No. 6. pp. 564-572.
@article{ebee83a108884b0ebb702b10f7f1b2e9,
title = "Establishment of CYP2D6 reference samples by multiple validated genotyping platforms",
abstract = "Cytochrome P450 2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6)), a highly polymorphic drug-metabolizing enzyme, is involved in the metabolism of one-quarter of the most commonly prescribed medications. Here we have applied multiple genotyping methods and Sanger sequencing to assign precise and reproducible CYP2D6 genotypes, including copy numbers, for 48 HapMap samples. Furthermore, by analyzing a set of 50 human liver microsomes using endoxifen formation from N-desmethyl-tamoxifen as the phenotype of interest, we observed a significant positive correlation between CYP2D6 genotype-assigned activity score and endoxifen formation rate (rs =0.68 by rank correlation test, P=5.3 × 10-8), which corroborated the genotype-phenotype prediction derived from our genotyping methodologies. In the future, these 48 publicly available HapMap samples characterized by multiple substantiated CYP2D6 genotyping platforms could serve as a reference resource for assay development, validation, quality control and proficiency testing for other CYP2D6 genotyping projects and for programs pursuing clinical pharmacogenomic testing implementation.",
author = "H. Fang and X. Liu and J. Ram{\'i}rez and N. Choudhury and Michiaki Kubo and Im, {H. K.} and A. Konkashbaev and Cox, {N. J.} and Ratain, {M. J.} and Y. Nakamura and O'Donnell, {P. H.}",
year = "2014",
month = "12",
day = "11",
doi = "10.1038/tpj.2014.27",
language = "English",
volume = "14",
pages = "564--572",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "6",

}

Fang, H, Liu, X, Ramírez, J, Choudhury, N, Kubo, M, Im, HK, Konkashbaev, A, Cox, NJ, Ratain, MJ, Nakamura, Y & O'Donnell, PH 2014, 'Establishment of CYP2D6 reference samples by multiple validated genotyping platforms', Pharmacogenomics Journal, vol. 14, no. 6, pp. 564-572. https://doi.org/10.1038/tpj.2014.27

Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. / Fang, H.; Liu, X.; Ramírez, J.; Choudhury, N.; Kubo, Michiaki; Im, H. K.; Konkashbaev, A.; Cox, N. J.; Ratain, M. J.; Nakamura, Y.; O'Donnell, P. H.

In: Pharmacogenomics Journal, Vol. 14, No. 6, 11.12.2014, p. 564-572.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Establishment of CYP2D6 reference samples by multiple validated genotyping platforms

AU - Fang, H.

AU - Liu, X.

AU - Ramírez, J.

AU - Choudhury, N.

AU - Kubo, Michiaki

AU - Im, H. K.

AU - Konkashbaev, A.

AU - Cox, N. J.

AU - Ratain, M. J.

AU - Nakamura, Y.

AU - O'Donnell, P. H.

PY - 2014/12/11

Y1 - 2014/12/11

N2 - Cytochrome P450 2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6)), a highly polymorphic drug-metabolizing enzyme, is involved in the metabolism of one-quarter of the most commonly prescribed medications. Here we have applied multiple genotyping methods and Sanger sequencing to assign precise and reproducible CYP2D6 genotypes, including copy numbers, for 48 HapMap samples. Furthermore, by analyzing a set of 50 human liver microsomes using endoxifen formation from N-desmethyl-tamoxifen as the phenotype of interest, we observed a significant positive correlation between CYP2D6 genotype-assigned activity score and endoxifen formation rate (rs =0.68 by rank correlation test, P=5.3 × 10-8), which corroborated the genotype-phenotype prediction derived from our genotyping methodologies. In the future, these 48 publicly available HapMap samples characterized by multiple substantiated CYP2D6 genotyping platforms could serve as a reference resource for assay development, validation, quality control and proficiency testing for other CYP2D6 genotyping projects and for programs pursuing clinical pharmacogenomic testing implementation.

AB - Cytochrome P450 2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6)), a highly polymorphic drug-metabolizing enzyme, is involved in the metabolism of one-quarter of the most commonly prescribed medications. Here we have applied multiple genotyping methods and Sanger sequencing to assign precise and reproducible CYP2D6 genotypes, including copy numbers, for 48 HapMap samples. Furthermore, by analyzing a set of 50 human liver microsomes using endoxifen formation from N-desmethyl-tamoxifen as the phenotype of interest, we observed a significant positive correlation between CYP2D6 genotype-assigned activity score and endoxifen formation rate (rs =0.68 by rank correlation test, P=5.3 × 10-8), which corroborated the genotype-phenotype prediction derived from our genotyping methodologies. In the future, these 48 publicly available HapMap samples characterized by multiple substantiated CYP2D6 genotyping platforms could serve as a reference resource for assay development, validation, quality control and proficiency testing for other CYP2D6 genotyping projects and for programs pursuing clinical pharmacogenomic testing implementation.

UR - http://www.scopus.com/inward/record.url?scp=84927178203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927178203&partnerID=8YFLogxK

U2 - 10.1038/tpj.2014.27

DO - 10.1038/tpj.2014.27

M3 - Article

C2 - 24980783

AN - SCOPUS:84927178203

VL - 14

SP - 564

EP - 572

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 6

ER -